As of September 29, 2026, Caribou Biosciences's top three insider holders are Rachel E. Haurwitz (President And Ceo, 3.37Mn shares), Barbara G Mcclung (Chief Legal Officer, 481.56K shares), Rachel E. Haurwitz (President And Ceo, 447.15K shares).
| # | Insider | Position | Direct | Indirect | Total | Share of Insiders | Last Filed |
|---|---|---|---|---|---|---|---|
| 1 | Barbara G Mcclung | Chief Legal Officer | 481,564 | 0 | 481,564 | 24.3% | 24 Feb, 2026 |
| 2 | Rachel E. Haurwitz | President And Ceo | 447,150 | 0 | 447,150 | 22.6% | 20 Feb, 2026 |
| 3 | Steven Kanner | Chief Scientific Officer | 431,556 | 0 | 431,556 | 21.8% | 21 Feb, 2025 |
| 4 | Syed Ali-Aamir Rizvi | Chief Medical Officer | 124,373 | 0 | 124,373 | 6.3% | 20 Jan, 2023 |
| 5 | Ryan Fischesser | Vp Of Finance And Controller | 118,854 | 0 | 118,854 | 6.0% | 22 Nov, 2024 |
| 6 | Ruhi Ahmad Khan | Chief Business Officer | 104,998 | 0 | 104,998 | 5.3% | 24 Feb, 2026 |
| 7 | Timothy P Kelly | Chief Technology Officer | 73,125 | 0 | 73,125 | 3.7% | 27 Feb, 2026 |
| 8 | Sriram Ryali | Chief Financial Officer | 72,360 | 0 | 72,360 | 3.7% | 20 Feb, 2026 |
| 9 | Tina M. Albertson | Chief Medical Officer | 68,523 | 0 | 68,523 | 3.5% | 24 Feb, 2026 |
| 10 | Jason O'Byrne | Chief Financial Officer | 59,224 | 0 | 59,224 | 3.0% | 22 Feb, 2024 |
Each row is that insider’s most recently reported position, from Form 4 filings over the last 60 months — which is why this total does not tie to the quarterly series above, where a quarter counts only the insiders who filed in it. Shares held through a fund or institutional portfolio are counted on the institutional ownership page instead.
| Date | Insider | Position | Transaction | Shares | Price | Value | Shares Held After | Ownership |
|---|---|---|---|---|---|---|---|---|
| 25 Feb, 2026 | Timothy P Kelly | Chief Technology Officer | Disposed S | 6,228 | $1.93 | $12.02K | 73,125 | Direct |
| 20 Feb, 2026 | Barbara G Mcclung | Chief Legal Officer | Acquired A | 45,000 | $0.00 | $0 | 488,502 | Direct |
| 20 Feb, 2026 | Tina M. Albertson | Chief Medical Officer | Acquired A | 55,000 | $0.00 | $0 | 69,589 | Direct |
| 20 Feb, 2026 | Ruhi Ahmad Khan | Chief Business Officer | Acquired A | 45,000 | $0.00 | $0 | 111,936 | Direct |
| 20 Feb, 2026 | Timothy P Kelly | Chief Technology Officer | Acquired A | 45,000 | $0.00 | $0 | 82,500 | Direct |
| 24 Feb, 2026 | Timothy P Kelly | Chief Technology Officer | Disposed S | 3,147 | $1.96 | $6.17K | 79,353 | Direct |
| 24 Feb, 2026 | Ruhi Ahmad Khan | Chief Business Officer | Disposed S | 6,938 | $1.96 | $13.60K | 104,998 | Direct |
| 24 Feb, 2026 | Barbara G Mcclung | Chief Legal Officer | Disposed S | 6,938 | $1.96 | $13.60K | 481,564 | Direct |
| 24 Feb, 2026 | Tina M. Albertson | Chief Medical Officer | Disposed S | 1,066 | $1.96 | $2.09K | 68,523 | Direct |
| 20 Feb, 2026 | Timothy P Kelly | Chief Technology Officer | Acquired A | 202,500 | $0.00 | $0 | 202,500 | Direct |
| 20 Feb, 2026 | Barbara G Mcclung | Chief Legal Officer | Acquired A | 202,500 | $0.00 | $0 | 202,500 | Direct |
| 20 Feb, 2026 | Tina M. Albertson | Chief Medical Officer | Acquired A | 247,500 | $0.00 | $0 | 247,500 | Direct |
| 20 Feb, 2026 | Ruhi Ahmad Khan | Chief Business Officer | Acquired A | 202,500 | $0.00 | $0 | 202,500 | Direct |
| 20 Feb, 2026 | David Lee Johnson | Director | Acquired A | 45,000 | $0.00 | $0 | 45,000 | Direct |
| 20 Feb, 2026 | Ran Zheng | Director | Acquired A | 45,000 | $0.00 | $0 | 45,000 | Direct |
| 20 Feb, 2026 | Andrew Guggenhime | Director | Acquired A | 45,000 | $0.00 | $0 | 45,000 | Direct |
| 20 Feb, 2026 | Nancy Whiting | Director | Acquired A | 45,000 | $0.00 | $0 | 45,000 | Direct |
| 20 Feb, 2026 | Dara Richardson-Heron | Director | Acquired A | 45,000 | $0.00 | $0 | 45,000 | Direct |
| 20 Feb, 2026 | Sriram Ryali | Chief Financial Officer | Acquired A | 55,000 | $0.00 | $0 | 72,360 | Direct |
| 20 Feb, 2026 | Rachel E. Haurwitz | President And Ceo | Acquired A | 151,700 | $0.00 | $0 | 447,150 | Direct |